SurVaxM is engineered to be highly immunogenic, and is delivered through simple subcutaneous injection. Read More


Survivin is an endogenous cellular protein that prevents tumor cell death. It is not, however, generally present in normal adult cells. Survivin is the target of MimiVax SurVaxM.

  • SurVaxM has been proven to inhibit tumor growth and prolong survival of animals with brain, ovarian, renal, and prostate cancers. It also induces the lymphocytes of cancer patients to kill his/her own tumor cells in the laboratory.
  • Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer immunology, immunotherapy, 2010; 598:1211-1221
  • Fenstermaker RA,. Ciesielski MJ. Development of a Survivin Vaccine (SurVaxM) for Malignant Glioma. Expert Rev Vaccines 2014; 13:377–385.
  • Ciesielski MJ, Qiu, J, Fenstermaker RA. Survivin as a Cancer Vaccine Target. J Vaccines Vaccin 5:3, 2014.

MimiVax Immunotherapy: SurVaxM

Read More

MimiVax, LLC

Elm & Carlton Streets

MRC 105

Buffalo, NY  14263


Pharmaceuticals for Oncology


MimiVax awarded US patent: "Survivin peptides as Cancer Vaccines" - May, 2011  Read More

MimiVax awarded patent in The Peoples Republic of China for "Survivin Peptides as Cancer Vaccines" - April, 2013   Read More

Phase I clinical trial of SurVaxM completed 2014. Read More

MimiVax SurVaxM

MimiVax awarded US patent: "Survivin Peptides for Auto-Immune Therapies"  - November, 2013  Read More

Phase I clinical trial of SurVaxM in multiple myeloma planned for 2015. Read More

Phase II clinical trial of SurVaxM in malignant glioma planned for 2015. Read More